Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

"We are pleased to announce last patient/last visit in our Phase 2 obesity study and look forward ... loss beyond those achieved with GLP-1 and GIP drugs," continued Dr. Spana.

This medication also mimics GLP-1, in addition to ... polypeptide (or GIP), which plays a role in fat metabolism. Beyond treating type 2 diabetes and obesity, GLP-1 drugs are showing surprising ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained widespread popularity as treatments for type 2 diabetes and obesity. In ...

As obesity rates rise, eligibility expands and curiosity about these medications grows ... a triple-hormone-receptor agonist combining GLP-1, GIP and glucagon receptors. Early trial data published ...

New obesity management medications, including glucagon-like peptide 1 receptor agonists (GLP-1RAs), have shown high efficacy in clinical trials. Among GLP-1RAs, liraglutide and semaglutide have ...